IL6 and COVID-19: Even if the effects observed may, to some extent, share similarities with the impact of dexamethasone (Horby et al, 2020) and tocilizumab (anti‐IL‐6) (Rossotti et al, 2020) on COVID‐19, IVM action is steady and strong in the golden hamsters and is not expected to block the effectors of inflammation but rather to dampen its initiation.